3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
15
Triple Negative Breast Neoplasms
5
Ovarian Neoplasms
4
Prostatic Neoplasms
3
Melanoma
3
Lymphoma
3
Lung Neoplasms
3
Endometrial Neoplasms
3
Uterine Cervical Neoplasms
2
Multiple Myeloma
2
Locally Advanced (Inoperable) or Metastatic Breast Cancer
2
Leukemia
2
Hematologic Neoplasms
2
Healthy Participants
2
Disease Progression
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Rectal Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Moderate Hepatic Impairment
1
Interventions
pembrolizumab
105
Specimen Handling
55
Magnetic Resonance Spectroscopy
48
Biopsy
47
Nivolumab
40
Paclitaxel
35
Gemcitabine
30
Radiosurgery
29
Carboplatin
28
Irinotecan
22
Ipilimumab
22
Cyclophosphamide
22
Cisplatin
22
trastuzumab deruxtecan
21
Leucovorin
19
Capecitabine
19
Fluorouracil
18
Cetuximab
18
Bevacizumab
18
130-nm albumin-bound paclitaxel
18
Pemetrexed
17
Fulvestrant
17
Drug Therapy
16
Docetaxel
16
Taxes
15
Oxaliplatin
15
olaparib
14
abemaciclib
14
Radiotherapy
14
palbociclib
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
capivasertib
×
1 year
×
Clear all
NCT07281833
2026-02-27
CAPIcorn
West German Study Group
Phase 3
Recruiting
250 enrolled